Stay updated on Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial
Sign up to get notified when there's something new on the Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial page.

Latest updates to the Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check37 days agoChange DetectedThe page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference1.0%
- Check44 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
- Check88 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check102 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
- Check109 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.3%
Stay in the know with updates to Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial page.